Tag Archives: open-xhr-start

GGN: Now Could Be A Good Time To Pick This High Yielder Up

Summary GGN invests in gold and natural resources, with an option overlay and the ability to use leverage. GGN’s is trading at an over 5% discount to its NAV, despite a history of trading at or above NAV. That could make now a good time to consider this relatively risky high yielder. GAMCO Global Gold, Natural Resources & Income Trust (NYSEMKT: GGN ) isn’t for the feint of heart. But if you can handle a little risk and have been looking for a way to add hard assets to your portfolio, now could be a good time to consider this closed-end fund, or CEF. And with an over 12% yield, paid monthly, you’ll be getting a nice income stream, too. Not your average bear GGN isn’t your run of the mill gold fund. This CEF’s portfolio is roughly 50% metals and mining stocks and 33% energy and energy services stocks. So roughly 80% of the fund is in sectors that have been, you could say, out of favor. Oil and related stocks have been the most recent market pariahs taking a toll on this CEF’s market price. However that doesn’t mean that you should avoid these assets. Hard assets and related industries can provide a valuable hiding place when markets are in turmoil or when inflation is rising quickly. They are often seen as a safe haven. It’s this diversification opportunity that leads investors to include some hard assets in their portfolios. So, the current malaise in mining and energy stocks can be looked at as a reason to avoid the sectors, or as a Blue Light Special opportunity for adding hard assets to your otherwise diversified portfolio-Just in case. But there’s more to GGN than just a focus on hard assets. It can also make use of leverage ( around 7% or so recently ) and an option overlay strategy. The primary goal of the fund is to provide investors with a high level of income, capital appreciation is a secondary goal. Thus, the fund writes options on the stocks it owns. And since volatility is the norm in the precious metals arena, there’s plenty of opportunity to take advantage of the options strategy to create income. Right now GGN pays $0.07 a share every month. That was recently cut from $0.09, a fact that should prepare you for income volatility here. However, even with that dividend cut, the CEF still pays a handsome yield of around 12%. Thus giving you high yield exposure to a broad asset class that could provide a safe haven if the markets tank. The leverage piece of the puzzle is more difficult to reconcile with the fund’s income objective. However, with rates historically low, GGN is taking advantage of an opportunity to access cheap debt. That’s a double edge sword, since leverage can enhance performance on the upside and exacerbate losses on the down side. There’s been more down than up lately, so it’s a good thing that leverage is pretty light at around 7%. This is a piece worth watching if you decide to step in here. That said, sister closed-end fund GAMCO Natural Resources, Gold & Income Trust (NYSE: GNT ) is another option if you want to avoid leverage, but it’s yield is a couple of percentage points lower. I’ll write about this CEF shortly. The real opportunity While owning an income producing security in out of favor industries is a good reason to be looking at GGN, it doesn’t get at the real opportunity right now. And that’s the discrepancy between GGN’s share price and its net asset value, or NAV. Historically, GGN has traded at or slightly above its NAV, with the Closed-end Fund Association pegging the average premium over the past five years at a little over 2%. But right now GGN is trading at discount of around 5% or so. The reason for this is likely two fold. First, investors have been selling off anything related to oil over the last six months or so as oil prices have fallen precipitously. That includes GGN. Second, year-end selling to lock in losses to offset gains elsewhere for tax purposes. GGN is a prime target for tax less selling since last year was a less than stellar one for the fund; the fund’s share price was down nearly 25% in 2014. (Total return, which includes distributions, was a loss of roughly 15%.) That’s not a guarantee that you’ll see a 7% price jump as 2015 progresses in addition to a 12% yield. But it does mean that GGN’s shares look like they are being put on an even deeper sale than the two sectors on which it is focused. So, if you want to own some hard assets “just in case,” now is a good time to take a look at GAMCO Global Gold, Natural Resources & Income Trust. That’s especially true if you have an income bent and prefer to outsource at least some of your investment activities.

Portfolio Update: Buying More PMs

Please note that this post is a little outdated due to the recent holiday break. Usually, I try to update the trades opened within the 24 hours from execution, but in recent times I haven’t been anywhere near the office (apart from an hour here or there). I did open two new trades just before New Year’s eve, so here is the update as well as a brief thinking process. Chart 1: Gold has shown incredible relative strength during the USD rally! Source: Short Side of Long Unless you have been living in a cave or under a rock, you surely would have noticed the amazing strength the U.S. Dollar has been showing in recent months. Whether it’s against the majors like the Euro, the Yen or the Australian dollar, or EM currencies such as the Ruble or Real, the greenback has been making up some serious ground. If we observe Chart 1, we should be able to see four major global macro asset classes: S&P 500, Treasury Long Bond, USD Index and Gold. Let us not focus on the stock and bond market for a second, and only pay attention to the recent action in the U.S. Dollar (inverted on the chart) and Gold. Majority of the time, negative correlation between the USD and Gold is high. So in plain English, usually but not always, Gold moving up means the U.S. Dollar is moving down, and vice versa. What should grab all of our attention is how powerful the recent USD rally has been and yet Gold has held its own (observe the blue box in Chart 1). Chart 2: Price is compressed in a technical triangle and it’s decision time Source: Short Side of Long The fact that Gold has barely sold off and still remains above $1,200 per ounce, at a similar price where it traded 18 months ago, indicates relative strength and buying interest. Other commodities, such as Crude Oil, have not been as lucky with greenback moving up so high. Eventually the U.S. Dollar rally will pause and take a breather, because nothing can keep rising vertically forever. It is my view that Gold will outperform when that time comes. Now… most trades would like to know when that will happen. Because I do not have a crystal ball, I cannot answer that question like other so-called “experts.” But what I can say is that the current price action in Gold shows a major compression in the form of a technical triangle. This pattern is edging closer and closer to a break in either direction, which should give us further clues (refer to Chart 2). I believe this break will be on the upside and I recently purchased some Gold via the SPDR Gold Trust ETF ( GLD). Depending on how the price behaves, this could either just be a short-term trade or a longer-term investment. Chart 3: Miners have been terrible performers since 2011 and appear cheap Source: Short Side of Long Furthermore, Gold Miners have become extremely oversold and now trade at dirt-cheap valuations. When compared to the Gold price itself, miners trade at the biggest discount since 2000… around the time the last major precious metals bull market started (please see Chart 3). This is even more true when we look at the Market Vectors Junior Gold Miners ETF ( GDXJ), which is down by almost 89% from the highest high in late 2010. I’ve started a small position here to test the waters (similar to Russia and Uranium if you refer to Chart 4). Also worth an important mention, I have closed my major hedge on Silver, which was originally opened in early July of 2014 just above $21 per ounce. This was one of my biggest trades in recent times and a gain of 24.5% is really, really huge. I plan to use these profits to purchase more PMs and average down my previous positions, which sit underwater. Moreover, despite a huge rally in the U.S. Dollar, I will continue to hold all my cash in this currency for the time being. My shorts on the Aussie Dollar also remain in place for now. Finally, the only other position I have opened recently is the Chinese H shares bet, but more on that in another post. Chart 4: Recent additions to the portfolio are PMs and Chinese stocks Source: Short Side of Long Disclosure: Biggest trades in the portfolio are long Precious Metals, long Chinese equities, short Australian Dollar and finally cash held in U.S. Dollar currency. Link to the original article on The Short Side Of Long

A New One Of A Kind Biotech ETF Hits The Market

Summary LifeSci Index Partners has just launched the BioShares Biotechnology Clinical Trials ETF. This ETF focuses on just those biotech firms with a primary product offering that is in a Phase 1, Phase 2 or Phase 3 clinical trial stage of development. Given that these companies have no current product sales, many of the stocks in this portfolio are essentially boom or bust propositions. This fund is the only one in the ETF universe that offers exclusive focus to these clinical trial firms. Biotechnology stocks have soared this past year – the iShares Nasdaq Biotechnology Index Fund (NASDAQ: IBB ) returned an impressive 34% in 2014 – so it’s not surprising that companies are stepping up their biotech offerings in order to take advantage of current demand. One of those offerings that hit the market in just the last week is attempting to differentiate itself by targeting a very unique niche of the market. The BioShares Biotechnology Clinical Trials ETF (NASDAQ: BBC ) invests in biotech firms with a primary product offering that is in a Phase 1, Phase 2 or Phase 3 clinical trial stage of development. According to the fund’s fact sheet: Clinical trials stage companies are typically younger, smaller companies which do not have a drug approved but instead focus on testing their experimental drug candidates in human clinical trials. While many biotech focused ETFs invest in these types of firms, this is believed to be the only ETF out there that focuses on these types of companies. Most biotech ETFs tend to be more heavily weighted towards the big established names. In the aforementioned iShares Biotechnology Index Fund, every one of the top nine holdings in the ETF which happens to include over 53% of the ETF’s total assets fall into the Large Growth Morningstar style box. These top holdings include titans like Biogen (NASDAQ: BIIB ), Celgene (NASDAQ: CELG ) and Amgen (NASDAQ: AMGN ). That’s fine if you want broad exposure to the biggest and baddest names in the sector but it doesn’t do you much good if you want to invest in the little guys who are trying to break out in the sector or have a promising new drug in the pipeline. Researching and investing in these names individually can be cumbersome, costly and very risky. Being able to invest in a broad basket of these types of companies (the fund has 68 holdings in all) represents a niche that could really appeal to investors. Top holdings in this ETF currently include Sage Therapeutics (NASDAQ: SAGE ), Infinity Pharmaceuticals (NASDAQ: INFI ) and Prothena (NASDAQ: PRTA ). The fund is still in its infancy but initial signs are positive. The fund has a mere $3M in assets, but it does trade around 35,000 shares a day currently, so liquidity is slowly becoming less of an issue. Plus, investors need to consider the risk in an ETF such as this. Given that these companies have no actual product sales and just experimental drugs in the pipeline, they’re essentially boom or bust propositions and should be considered risky. Conclusion It’s easy to trade individual stocks when they’re well followed and well researched but an ETF is perfect for a niche product such as this. The 0.85% expense ratio isn’t particularly onerous considering you’ve got biotech specialists managing the product for you. Given biotech’s current popularity and the fact that there doesn’t appear ETF offering exclusive exposure to these clinical trial firms, this ETF should have some success carving out a special niche for investors. Now that you’ve read this, are you Bullish or Bearish on ? Bullish Bearish Sentiment on ( ) Thanks for sharing your thoughts. Why are you ? Submit & View Results Skip to results » Share this article with a colleague